Literature DB >> 10023661

Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2.

H Sheng1, J Shao, C A O'Mahony, L Lamps, D Albo, P C Isakson, D H Berger, R N DuBois, R D Beauchamp.   

Abstract

The precise role of TGF-beta in colorectal carcinogenesis is not clear. The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-beta in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by >75% following TGF-beta1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-beta1. These 'TGF-beta-resistant' cells (RIE-Tr) were continuously exposed to TGF-beta for >50 days. Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose. RIE-Tr cells demonstrated TGF-beta-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis. The RIE-Tr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-beta receptor (TbetaRII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin. Most RIE-Tr subclones that expressed low levels of TbetaRII and high levels of COX-2 were tumorigenic. Those subclones that express abundant TbetaRII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of TbetaRII, increased expression of COX-2, and the ability to form colonies in Matrigel were all reversible upon withdrawal of exogenous TGF-beta1 for the RIE-Tr cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023661     DOI: 10.1038/sj.onc.1202397

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  Hormonal regulation of physiological cell turnover and apoptosis.

Authors:  R D Medh; E B Thompson
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

2.  TGF-beta signaling in colon cancer cells.

Authors:  Fazhi Li; Yanna Cao; Courtney M Townsend; Tien C Ko
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

Review 3.  Diversity of axin in signaling pathways and its relation to colorectal cancer.

Authors:  Nighat Parveen; Mahboob Ul Hussain; Arshad A Pandith; Syed Mudassar
Journal:  Med Oncol       Date:  2010-10-30       Impact factor: 3.064

4.  Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta(1) in immortalized mouse colonocytes expressing oncogenic Ras.

Authors:  Christopher D Roman; Jason Morrow; Robert Whitehead; R Daniel Beauchamp
Journal:  J Gastrointest Surg       Date:  2002 May-Jun       Impact factor: 3.452

5.  Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.

Authors:  Ying-Wei Xue; Qi-Fan Zhang; Zhi-Bing Zhu; Qi Wang; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Synergistic regulation of COX-2 expression by bombesin and transforming growth factor-beta.

Authors:  Yan-Shi Guo; Zihong Chen; Xiao-Dong Wen; Tien C Ko; Courtney M Townsend; Mark R Hellmich
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

7.  Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells.

Authors:  Zhi-Hong Zhang; Qin Ouyang; Hua-Tian Gan
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

Review 8.  TGF-beta signaling alterations and susceptibility to colorectal cancer.

Authors:  Yanfei Xu; Boris Pasche
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

9.  TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.

Authors:  Baohan T Vo; Derrick Morton; Shravan Komaragiri; Ana C Millena; Chelesie Leath; Shafiq A Khan
Journal:  Endocrinology       Date:  2013-03-20       Impact factor: 4.736

10.  The genomics of colorectal cancer: state of the art.

Authors:  Andrew D Beggs; Shirley V Hodgson
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.